Shared on 01 Nov 25
Fair value Decreased 2.54%Analysts have reduced their price target for DSM-Firmenich from €108.45 to €105.70. They cite slightly lower revenue growth expectations and modest adjustments to valuation assumptions as the reasons for this change.
Shared on 18 Oct 25
Fair value Decreased 0.46%Health And Bio-Based Trends Will Drive Future Success
The fair value estimate for DSM-Firmenich has been slightly reduced from €108.95 to €108.45. This change reflects updated analyst projections citing modest adjustments to revenue growth and profit margin expectations.
Shared on 04 Oct 25
Fair value Decreased 4.97%Health And Bio-Based Trends Will Drive Future Success
Analysts have lowered their price target for DSM-Firmenich from €114.65 to €108.95. They cite reduced expectations for revenue growth and a higher discount rate, despite a marginal improvement in profit margins and future valuation metrics.
Shared on 19 Sep 25
Fair value Decreased 2.59%Health And Bio-Based Trends Will Drive Future Success
Consensus price targets for DSM-Firmenich have been revised downward due to persistent earnings headwinds, weaker-than-expected Nutrition demand, and margin pressures from currency and input costs, partially offset by confidence in long-term synergies and portfolio optimization, resulting in a new fair value of €114.65 (down from €117.70). Analyst Commentary Bearish analysts point to persistent earnings headwinds and industry-wide pricing pressure driving down near-term profitability.
Shared on 04 Sep 25
Health And Bio-Based Trends Will Drive Future Success
With both the future P/E ratio and consensus revenue growth forecasts remaining essentially unchanged, analysts have maintained DSM-Firmenich’s fair value estimate at €117.70. What's in the News DSM-Firmenich launched Lacteol® diarrhEase™ Kids, a top pediatrician-recommended postbiotic for children as young as six months, in the U.S. market.
Shared on 01 May 25
Fair value Decreased 5.85%Health And Bio-Based Trends Will Drive Future Success
Shared on 23 Apr 25
Focusing On Taste, Texture, And Health Will Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 1.39%Focusing On Taste, Texture, And Health Will Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Focusing On Taste, Texture, And Health Will Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 0.19%Focusing On Taste, Texture, And Health Will Strengthen Future Prospects
AnalystConsensusTarget has increased revenue growth from 3.3% to 3.6%.
Shared on 26 Mar 25
Fair value Decreased 0.47%Focusing On Taste, Texture, And Health Will Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Focusing On Taste, Texture, And Health Will Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Increased 4.26%Focusing On Taste, Texture, And Health Will Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.